Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Orthop Relat Res. 2012 Feb;470(2):395-401. doi: 10.1007/s11999-011-2170-x.

Tantalum augments for Paprosky IIIA defects remain stable at midterm followup.

Author information

  • 1Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA. ddelgaizo@gmail.com

Abstract

BACKGROUND:

Initial reports with short-term followup of porous tantalum acetabular components and augments for Paprosky IIIA acetabular defects demonstrate high hip scores, low rates of aseptic loosening, and low rates of complications. However, longer-term followup with a larger cohort is needed to determine the durability of these reconstructions.

QUESTIONS/PURPOSES:

We therefore determined the functional scores, rates of aseptic loosening, and complications in patients with Paprosky IIIA acetabular defects treated with porous tantalum acetabular components and augments.

METHODS:

We retrospectively reviewed 37 acetabular revisions in 36 patients (one patient with bilateral revisions) treated with a porous tantalum acetabular component and augment. All patients had defects classified as Type IIIa using the system of Paprosky et al. Harris hip scores were obtained and radiographic examination was performed before surgery and through most recent followup. The minimum followup was 26 months (mean, 60 months; range, 26-106 months).

RESULTS:

One patient developed aseptic loosening of the acetabular reconstruction requiring revision; seven other patients required further surgery for periprosthetic femoral fracture (two), acute infection (three), and recurrent dislocation (two). Thirty-five of 37 hips had no or occasional pain at final followup. Mean Harris hip scores improved from 33.0 preoperatively (range, 12.6-58.7) to 81.5 postoperatively (range, 27.0-99.8).

CONCLUSIONS:

Although the complication rate requiring further surgery was considerable, most patients with these reconstructions had pain relief and reasonable function with low rates of loosening at midterm followup.

LEVEL OF EVIDENCE:

Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

PMID:
22090355
[PubMed - indexed for MEDLINE]
PMCID:
PMC3254742
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1A–B
Fig. 2A–B
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk